Two RRT Modalities Offer Similar Survival
PRAGUE—Two forms of renal replacement therapy (RRT) for end-stage renal disease are associated with similar rates of mortality overall and from cardiovascular (CV) causes, according to a new study.
All articles by Daniel M. Keller, PhD
Similar Survival Rates for Hemodiafiltration and Hemodialysis
PRAGUE—End-stage renal disease patients on post-dilution online hemodiafiltration (HDF) or high-flux hemodialysis (HD) have the same overall survival and non-fatal cardiovascular (CV) event rates, new findings show.
Survival Better with HD than PD in CHF Patients
PRAGUE—For patients with congestive heart failure (CHF) who initiate maintenance dialysis, those starting on peritoneal dialysis (PD) have a significantly greater death risk than those starting on hemodialysis (HD), according to a French study.
PP Declines Predict Worse HD Patient Survival
PRAGUE—Decreases in pulse pressure (PP), and to a lesser extent increases, predict worse survival in the first year for patients new to hemodialysis (HD), new findings suggest.
LDL Lowering Fails to Slow Renal Disease Progression
PRAGUE—Lowering LDL cholesterol (LDL) can prevent or even reverse atherosclerosis, but it does not do the same for the progression of chronic kidney disease (CKD).
HDL from CDK Patients Loses Vasoprotective Effects
PRAGUE—HDL cholesterol (HDL) in patients with chronic kidney disease (CKD) loses its protective effect on vascular endothelium, new findings suggest. Rather than supporting the beneficial functions of the endothelium, it appears to become pro-inflammatory and inhibit them.
NP-Based Program Helps Control CKD Cardiac Risk Factors
PRAGUE—A multifactorial intervention using a polydrug and lifestyle treatment strategy with nurse practitioner (NP) support can improve management of some cardiovascular (CV) risk factors and reduced the number of physician visits by patients with chronic kidney disease (CKD).
Paricalcitol Superior for Lowering iPTH
The drug was more likely than cinacalcet to achieve a 50 percent or greater decrease in iPTH from baseline.
BP Meds at Bedtime Reduce CVD Risk
PRAGUE—Taking antihypertensive medications at bedtime significantly reduces cardiovascular disease (CVD) risk compared with ingesting the drugs upon awakening, according to researchers.
Short-Course Rituximab Produces Long-Term Remissions of ANCA Vasculitis
PRAGUE—A single four-week course of rituximab was as effective as 18 months of standard therapy with daily oral cyclophosphamide (CyP) and azathioprine (AZA) for induction and maintenance of remission in patients with severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). For either treatment, the number, rate, and severity of adverse events did not differ.
- Loading...
Loading...
Loading... 
Loading...